EFFECT OF PIPERAZINE OESTRONE SULPHATE ON SERUM LIPIDS AND LIPOPROTEINS IN MENOPAUSAL WOMEN

Publisher Website
Google Scholar
Abstract
Twenty menopausal women and 2 women with gonadal dysgenesis were treated with piperazine estrone sulfate 1.5-3 mg daily on a cyclical basis for a period of 6 mo. Fasting serum lipids and lipoprotein esterified fatty acid indices (EFI) were estimated before starting treatment and after 3 and 6 mo. There were small falls in serum cholesterol (significant at 3 mo.) and .beta.-lipoprotein EFI (significant at 6 mo.). Serum triglyceride and pre-.beta.-lipoprotein EFI rose significantly at 3 and 6 mo. Serum total phospholipid levels were reduced (significant at 6 mo.) with most marked changes in the sphingomyelin fraction. Other parameters were not significantly altered.